This trial is conducted in Europe. the aim of this trial is to compare the pharmacokinetic profile of liraglutide between administrations in the thigh versus the abdomen and between administrations in the upper arm versus the abdomen.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
21
Single dose of 0.60 mg administered subcutaneously in three different injection sites on three separate dosing visits
Novo Nordisk Investigational Site
Neuss, Germany
Area under the Curve (AUC) of liraglutide for each injection site
AUC
Cmax, maximum concentration
tmax, time to maximum concentration
t½, terminal half-life
Terminal elimination rate constant
Relative Bioavailability
Adverse events
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.